CAS 189198-30-9|Pactimibe
| Common Name | Pactimibe | ||
|---|---|---|---|
| CAS Number | 189198-30-9 | Molecular Weight | 416.59700 |
| Density | 1.071 | Boiling Point | 604.4ºC at 760 mmHg |
| Molecular Formula | C25H40N2O3 | Melting Point | / |
| MSDS | / | Flash Point | 319.3ºC |
Names
| Name | 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid |
|---|---|
| Synonym | More Synonyms |
Pactimibe BiologicalActivity
| Description | Pactimibe (CS-505 free base) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively[1]. Pactimibe (CS-505 free base) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe (CS-505 free base) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe (CS-505 free base) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity[2]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular Disease |
| Target | ACAT1:4.9 μM (IC50) ACAT2:3.0 μM (IC50) ACAT:2 μM (IC50, in the liver) ACAT:2.7 μM (IC50, in macrophages) ACAT:4.7 μM (IC50, in THP-1 cells) oleoyl-CoA:5.6 μM (Ki) cholesteryl ester formation:6.7 μM (IC50) |
| In Vitro | Pactimibe (CS-505 free base) induces moderate ACAT inhibition in monocyte-derived macrophages, leading to the suppression of foam cell formation[2]. |
| In Vivo | Pactimibe (CS-505 free base; 60 and 200 mg/kg/day; oral gavage; twice a day; 12 weeks) induces an inhibition for ACAT-1 and ACAT-2, causing a reduction of plasma cholesterol but no influence on macrophage- or collagen-positive areas[3]. Animal Model: Male C57BL/6J ApoE−/− mice aged 8-week-old[3] Dosage: 60 and 200 mg/kg/day Administration: Oral gavage; twice a day; 12 weeks Result: Decreased plasma cholesterol levels by 39% and 74% at the administration of 60 and 200 mg/kg/day |
| References | [1]. Naoki Terasaka, et al. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis. 2007 Feb;190(2):239-47. [2]. Ken Kitayama, et al. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Eur J Pharmacol. 2006 Jul 1;540(1-3):121-30. [3]. Yasunobu Yoshinaka, et al. A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice. Atherosclerosis. 2010 Nov;213(1):85-91. |
Chemical & Physical Properties
| Density | 1.071 |
|---|---|
| Boiling Point | 604.4ºC at 760 mmHg |
| Molecular Formula | C25H40N2O3 |
| Molecular Weight | 416.59700 |
| Flash Point | 319.3ºC |
| Exact Mass | 416.30400 |
| PSA | 69.64000 |
| LogP | 5.77610 |
| Vapour Pressure | 1.86E-15mmHg at 25°C |
| Index of Refraction | 1.547 |
| InChIKey | TXIIZHHIOHVWJD-UHFFFAOYSA-N |
| SMILES | CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21 |
Synonyms
| UNII-D874R9PZ9T |
| Pactimibe |
